Avinger Inc.

Avinger, Inc. (NASDAQ: AVGR) is a medical device company operating in the commercial phase. The company specializes in creating, manufacturing, and selling catheter-based systems that use real-time imaging to assist physicians in the minimally invasive treatment of patients suffering from peripheral artery disease (PAD). Additionally, they offer the Panther is family of catheters, an image-guided atherectomy system that enables physicians to remove arterial plaque in PAD patients.

Recent Financial and Business Updates:

• Second Quarter Income Statement Review:
  • The company generated USD2.0 million in revenue, with a gross margin of 30%.
  • In comparison, during the first quarter of 2023, the gross margin was also 30%, but it was slightly higher at 34% in the first quarter of 2022 and 31% in the second quarter of 2022.
  • Operating expenses for the second quarter of 2023 decreased to USD4.3 million, down from USD4.9 million in the first quarter of 2023 and USD4.4 million in the second quarter of 2022, indicating the company's commitment to maintaining an efficient cost structure.
  • The net loss and comprehensive loss in the second quarter of 2023 amounted to USD4.2 million.
  • In terms of Adjusted EBITDA, a non-GAAP financial measure mentioned in this press release, there was an improvement, with a loss of USD3.4 million in the second quarter of 2023.
• Balance Sheet Review:
  • Total assets amounted to USD16.94 million as on June 30, 2023.
  • Total current liabilities amounted to USD22.443 million as on June 30, 2023.
• Business Update:
  • The company has officially launched its Tigereye® ST, the next-generation system for image-guided crossing of chronic total occlusions (CTOs). With the initiation of full commercial launch, all current and prospective accounts can now order the Tigereye ST device.
  • Before going into full commercial operation, Avinger initiated a restricted introduction of Tigereye ST at 11 medical centers in the United States. During this phase, approximately 50 CTO procedures were carried out using Tigereye ST, involving the participation of 13 physicians.
  • Avinger, Inc (AVGR) has done a one-for-fifteen (1-15) reverse split of its Common Stock. The reverse stock split became effective on Wednesday, September 13, 2023.
    

Technical Observation (on the daily chart)

The Relative Strength Index (RSI) over a 14-day period is currently in the oversold zone at levels of 71.52, with expectations of some consolidation or a healthy short-term correction before the continuation of the upward momentum. The stock has given a return of 210.90% over a period of three trading sessions, due to the announcement of commercialisation of its Tigereye ST. The current price is above both 21-period SMA and 50-period SMA indicating a short-term bullish momentum, with expectations of these SMAs acting as support levels, in case of correction in the stock price.

As per the above-mentioned price action, recent key business and financial updates, momentum in the stock over the last month, and technical indicators analysis, a “WATCH” rating is recommended for Avinger Inc. (NASDAQ: AVGR) based on the current price of USD12.81 as on September 20, 2023, at 8:10 am PDT.

Individuals can evaluate the stock based on the support and resistance levels provided in the report in case of keen interest taking into consideration the risk-reward scenario. 

Markets are trading in a highly volatile zone currently due to certain macro-economic issues and prevailing geopolitical tensions. Therefore, it is prudent to follow a cautious approach while investing. 

Related Risk: This report may be looked at from a high-risk perspective and a recommendation is provided for a short duration. This report is solely based on technical parameters, and the fundamental performance of the stocks has not been considered in the decision-making process. Other factors which could impact the stock prices include market risks, regulatory risks, interest rates risks, currency risks, social and political instability risks etc. 

How to Read the Charts?

The yellow colour line reflects the 21-period simple moving average (SMA) while the blue line indicates the 50- period simple moving average (SMA). SMA helps to identify existing price trends. If the prices are trading above the 21-period and 50-period moving average, then it shows prices are currently trading in a bullish trend.

The orange colour line in the chart’s lower segment reflects the Relative Strength Index (14-Period) which indicates price momentum and signals momentum in trend. A reading of 70 or above suggests overbought status while a reading of 30 or below suggests an oversold status.

The red and green colour bars in the chart’s lower segment show the volume of the stock. The volume is the number of shares that changed hands during a given day. Stocks with high volumes are more liquid than stocks with lesser volume as liquidity in stocks helps with easier and faster execution of the order.

The Orange colour lines are the trend lines drawn by connecting two or more price points and used for trend identification purposes. The trend line also acts as a line of support and resistance.

Technical Indicators Defined: -

Support: A level at which the stock prices tend to find support if they are falling, and a downtrend may take a pause backed by demand or buying interest. Support 1 refers to the nearby support level for the stock and if the price breaches the level, then Support 2 may act as the crucial support level for the stock. 

Resistance: A level at which the stock prices tend to find resistance when they are rising, and an uptrend may take a pause due to profit booking or selling interest. Resistance 1 refers to the nearby resistance level for the stock and if the price surpasses the level, then Resistance 2 may act as the crucial resistance level for the stock. 

Stop-loss: It is a level to protect further losses in case of unfavourable movement in the stock prices. 

The reference date for all price data, currency, technical indicators, support, and resistance levels is September 20, 2023. The reference data in this report has been partly sourced from REFINITIV. 

Abbreviations

CMP: Current Market Price

SMA: Simple Moving Average

RSI: Relative Strength Index

USD: United States dollar 

Note: Trading decisions require a thorough analysis by individual. Technical reports in general chart out metrics that may be assessed by individuals before any stock evaluation. The above are illustrative analytical factors used for evaluating the stocks; other parameters can be looked at along with additional risks per se. Past performance is neither an indicator nor a guarantee of future performance.

Disclaimer - This report has been issued by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and prepared by Kalkine and its related bodies corporate authorised to provide general financial product advice. Kalkine.com.au and associated pages are published by Kalkine.

Any advice provided in this report is general advice only and does not take into account your objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Statement or other offer document for the securities or other financial products referred to in Kalkine reports. You should obtain a copy of the relevant Product Disclosure Statement, Information Statement or offer document and consider the statement or document before making any decision about whether to acquire the security or product.

You should also seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice in this report or on the Kalkine website. Not all investments are appropriate for all people.

The information in this report and on the Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of information contained in its reports, newsletters and websites. All information represents our views at the date of publication and may change without notice.

Kalkine does not guarantee the performance of, or returns on, any investment. To the extent permitted by law, Kalkine excludes all liability for any loss or damage arising from the use of this report, the Kalkine website and any information published on the Kalkine website (including any indirect or consequential loss, any data loss or data corruption). If the law prohibits this exclusion, Kalkine hereby limits its liability, to the extent permitted by law, to the resupply of services. Please note past performance is neither an indicator nor a guarantee of future performance.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this report or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website including entities covered in this Report.